Home›Clinical trials›Tennessee

GLP-1 clinical trials in Tennessee: 26 recruiting now

By John Samaras, EditorRegistry checked September 4, 2026

26 GLP-1 clinical trials are recruiting at 41 sites in 13 cities across Tennessee. Every site below is listed with its city and, where the sponsor publishes one, the number to call.

Every study recruiting in Tennessee

  1. A Phase 4, Prospective, Open-Label, Single-Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab

    Phase 4. Eli Lilly and Company plans to enroll 200 participants.

    A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people ease psoriatic arthritis.

    Who can join. Adults 18+, have psoriatic arthritis, BMI 27+.

    2 sites in Tennessee

    • West Tennessee Research Institute, Jackson. 731-633-0145
    • AARA Clinical Research - Murfreesboro Medical Clinic, Murfreesboro. 480-626-6650

    NCT06864026 on ClinicalTrials.gov. See whether you qualify.

  2. PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes

    Phase 4. Brigham and Women's Hospital plans to enroll 6,000 participants.

    A study testing whether a GLP-1 medicine, semaglutide, can help people lower blood sugar.

    Who can join. Adults 40 to 80, have type 2 diabetes.

    1 site in Tennessee

    • Vanderbilt University Medical Center, Nashville. 615-421-3082

    NCT05390892 on ClinicalTrials.gov. See whether you qualify.

  3. A Phase 4, Prospective, Open-Label, Single Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab

    Phase 4. Eli Lilly and Company plans to enroll 200 participants.

    A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people calm psoriasis.

    Who can join. Adults 18+, have psoriasis, BMI 27+.

    1 site in Tennessee

    • DelRicht Research - Thompson's Station, Smyrna. 629-895-1775

    NCT06857942 on ClinicalTrials.gov. See whether you qualify.

  1. Tirzepatide in PWS, HO and GNSO

    Phase 4. Grace Kim plans to enroll 36 participants.

    A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help people with Prader-Willi syndrome lose weight.

    Who can join. Adults 18 to 26, have Prader-Willi syndrome, BMI 30+.

    1 site in Tennessee

    • Vanderbilt University Medical Center, Nashville. 6158754274

    NCT06901245 on ClinicalTrials.gov. See whether you qualify.

  2. A Clinical Study to Compare Efficacy and Safety of Two Different Doses of CagriSema and Semaglutide in Participants With Obesity

    Phase 3. Novo Nordisk A/S plans to enroll 2,500 participants.

    A study testing whether a study medicine from Novo Nordisk, cagrisema, can help people with type 2 diabetes lose weight.

    Who can join. Adults 18+, have obesity, BMI 35+.

    5 sites in Tennessee
    • Jackson Clinic, Jackson
    • Holston Medical Group, Kingsport
    • CNS Healthcare, Memphis
    • HealthStar Physicians, PC, Morristown
    • Clinical Research Associates, Nashville

    NCT07564414 on ClinicalTrials.gov. See whether you qualify.

  3. LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced

    Phase 3. Boehringer Ingelheim plans to enroll 1,800 participants.

    A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people reduce liver fat.

    Who can join. Adults 18+, have fatty liver disease (also called MASH or NASH) with liver scarring (fibrosis).

    3 sites in Tennessee

    NCT06632444 on ClinicalTrials.gov. See whether you qualify.

  4. LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

    Phase 3. Boehringer Ingelheim plans to enroll 1,590 participants.

    A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people reduce liver fat.

    Who can join. Adults 18+, have fatty liver disease (also called MASH or NASH), BMI 25+.

    3 sites in Tennessee

    NCT06632457 on ClinicalTrials.gov. See whether you qualify.

  5. A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

    Phase 3. Eli Lilly and Company plans to enroll 4,500 participants.

    A study testing whether a GLP-1, GIP and glucagon medicine from Lilly, retatrutide, can help people reduce liver fat.

    Who can join. Adults 18+, have fatty liver disease (MASLD), BMI 25+.

    2 sites in Tennessee

    • Galen Medical Group - Galen Hepatology, Chattanooga. 423-653-0842
    • Gastro One (Walnut Run Road), Cordova

    NCT07165028 on ClinicalTrials.gov. See whether you qualify.

  6. Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease

    Phase 3. Eli Lilly and Company plans to enroll 1,205 participants.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people improve blood flow in the legs.

    Who can join. Adults 18+, have peripheral artery disease (poor blood flow in the legs), BMI 23+.

    2 sites in Tennessee

    • The Jackson Clinic, Jackson. 731-660-8396
    • East Coast Institute for Research - Jefferson City, Jefferson City

    NCT07223593 on ClinicalTrials.gov. See whether you qualify.

  7. A Randomized, Open-label, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron

    Phase 3. AstraZeneca plans to enroll 1,200 participants.

    A study testing whether a GLP-1 medicine, semaglutide, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18+, have type 2 diabetes, BMI 23+.

    2 sites in Tennessee

    • Research Site, Memphis
    • Research Site, Morristown

    NCT07662213 on ClinicalTrials.gov. See whether you qualify.

The other 16 studies recruiting in Tennessee

  1. A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar

    Phase 3. Boehringer Ingelheim plans to enroll 600 participants.

    A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18+, have type 2 diabetes, BMI 23+.

    2 sites in Tennessee

    NCT07754461 on ClinicalTrials.gov. See whether you qualify.

  2. A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

    Phase 3. Eli Lilly and Company plans to enroll 125 participants.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people lose weight.

    Who can join. Children and teens 6 to 17, have obesity.

    1 site in Tennessee

    NCT06672549 on ClinicalTrials.gov. See whether you qualify.

  3. A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities

    Phase 3. Eli Lilly and Company plans to enroll 150 participants.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people lose weight.

    Who can join. Children and teens 12 to 17, have obesity.

    1 site in Tennessee

    • Vanderbilt Health One Hundred Oaks, Nashville

    NCT06672939 on ClinicalTrials.gov. See whether you qualify.

  4. Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative

    Phase 3. Eli Lilly and Company plans to enroll 350 participants.

    A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people with ulcerative colitis calm gut inflammation.

    Who can join. Adults 18 to 70, have ulcerative colitis, BMI 27+.

    1 site in Tennessee

    • Gastroenterology Center Of The Midsouth, Cordova

    NCT06937086 on ClinicalTrials.gov. See whether you qualify.

  5. Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity

    Phase 3. Eli Lilly and Company plans to enroll 290 participants.

    A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people with Crohn's disease calm gut inflammation.

    Who can join. Adults 18 to 70, have Crohn's disease, BMI 27+.

    1 site in Tennessee

    • Gastroenterology Center Of The Midsouth, Cordova

    NCT06937099 on ClinicalTrials.gov. See whether you qualify.

  6. A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

    Phase 3. Eli Lilly and Company plans to enroll 800 participants.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people ease joint pain.

    Who can join. Adults 18+, have osteoarthritis (joint pain), BMI 27+.

    1 site in Tennessee

    NCT07153471 on ClinicalTrials.gov. See whether you qualify.

  7. A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

    Phase 3. Novo Nordisk A/S plans to enroll 460 participants.

    A study testing whether a study medicine from Novo Nordisk, cagrilintide, can help people lose weight.

    Who can join. Children and teens 8 to 18, are overweight.

    1 site in Tennessee

    • LifeDoc Health, Memphis

    NCT07253285 on ClinicalTrials.gov. See whether you qualify.

  8. A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity

    Phase 2. Novo Nordisk A/S plans to enroll 230 participants.

    A study testing whether an investigational medicine from Novo Nordisk, NNC0662-0419, can help people lose weight.

    Who can join. Adults 18+, have obesity, BMI 30+.

    3 sites in Tennessee

    • Holston Medical Group_Bristol, Bristol
    • Holston Medical Group, Kingsport
    • Clinical Research Associates, Nashville

    NCT07639021 on ClinicalTrials.gov. See whether you qualify.

  9. A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity

    Phase 2. Eli Lilly and Company plans to enroll 1,481 participants.

    A study testing whether an investigational medicine from Lilly, LY3305677, can help people lose weight.

    Who can join. Adults 18 to 75, have obesity, BMI 27+.

    1 site in Tennessee

    NCT06143956 on ClinicalTrials.gov. See whether you qualify.

  10. Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder

    Phase 2. T. John Winhusen, PhD plans to enroll 310 participants.

    A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help people with opioid use disorder cut down on opioids.

    Who can join. Adults 18+, have opioid use disorder, BMI 23+.

    1 site in Tennessee

    • Vanderbilt University Medical Center, Nashville. 615-585-9889

    NCT06651177 on ClinicalTrials.gov. See whether you qualify.

  11. GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV

    Phase 2. Vanderbilt University Medical Center plans to enroll 200 participants.

    A study testing whether a GLP-1 medicine, semaglutide, can help people with HIV drink less.

    Who can join. Adults 18 to 89, have HIV, BMI 23+.

    1 site in Tennessee

    • Vanderbilt University Medical Center, Nashville. 615-421-3508

    NCT07221214 on ClinicalTrials.gov. See whether you qualify.

  12. Resistance Exercise and Incretin Mimetic for Cardiometabolic Health in Survivors of ALL With Obesity

    Phase 2. St. Jude Children's Research Hospital plans to enroll 20 participants.

    A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help survivors of acute lymphoblastic leukemia lose weight.

    Who can join. Adults 18+, are survivors of acute lymphoblastic leukemia, BMI 27+.

    1 site in Tennessee

    • St. Jude Children's Research Hospital, Memphis. 888-226-4343

    NCT07228741 on ClinicalTrials.gov. See whether you qualify.

  13. A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes

    Phase 2. Novo Nordisk A/S plans to enroll 270 participants.

    A study testing whether an investigational medicine from Novo Nordisk, NNC0662-0419, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18 to 75, have type 2 diabetes.

    1 site in Tennessee

    • CNS Healthcare, Memphis

    NCT07415954 on ClinicalTrials.gov. See whether you qualify.

  14. A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes

    Phase 2. Novo Nordisk A/S plans to enroll 300 participants.

    A study testing whether an investigational medicine from Novo Nordisk, UBT251, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18 to 75, have type 2 diabetes.

    1 site in Tennessee

    • LifeDoc Health, Memphis

    NCT07668388 on ClinicalTrials.gov. See whether you qualify.

  15. GLP-1Ra Impact on Metabolic Outcomes in Stage 2 T1DM While Receiving Teplizumab

    Phase 1. Vanderbilt University Medical Center plans to enroll 24 participants.

    A study testing whether a GLP-1 medicine, semaglutide, can help people with type 1 diabetes lower blood sugar.

    Who can join. Ages 12 to 50, have type 1 diabetes, BMI 18+.

    1 site in Tennessee

    NCT06338553 on ClinicalTrials.gov. See whether you qualify.

  16. Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse

    Phase 1. Novo Nordisk A/S plans to enroll 114 participants.

    A study testing whether a study medicine from Novo Nordisk, cagrilintide, can help people lose weight.

    Who can join. Adults 18+, have obesity, BMI 30+.

    1 site in Tennessee

    • Holston Medical Group_Bristol, Bristol

    NCT07607587 on ClinicalTrials.gov. See whether you qualify.

Source: ClinicalTrials.gov, the federal registry, read September 4, 2026. Open a study's registry record before you call: it can close to new participants at any time. GLP Chart does not enroll anyone, is not paid for clinical-trial referrals and has no relationship with any sponsor or site on this page.

Screening for a study can take weeks. If you need the drug now, Strut Health is the cheapest cash route on the chart, from $149 a month. That price buys compounded semaglutide, a pharmacy-made version that is not FDA-approved and is not Wegovy, Ozempic, Zepbound or Mounjaro.

Visit Strut Health ↗

Clinical trials by state

Every state with a GLP-1 study recruiting today. 48 of them.

John Samaras, editor of GLP Chart
Written and edited by John SamarasAbout this siteContact
Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.